Stockreport

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Prelude Therapeutics Incorporated  (PRLD) 
PDF Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Associat [Read more]